Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
|
|
- Maximillian Roberts
- 5 years ago
- Views:
Transcription
1 The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country. Study No.: SALMP/AH91/D89 Title: A phase III, multi-centre, double-blind, placebo controlled, parallel group study assessing the efficacy and safety of inhaled salmeterol xinafoate (Serevent ) 50 micrograms BD via the Diskhaler when added to the existing treatment of moderate to severe asthmatic children. Rationale: The study was designed to assess the efficacy and safety of inhaled salmeterol xinafoate (SAL) 50µg twice daily (BD) when added to the existing therapy for moderate to severe asthmatic children. Phase: III Study Period: 14 March 1992 to 14 March 1993 Study Design: Multi-centre, double-blind, placebo-controlled, parallel-group study Centres: 78 centres in the United Kingdom Indication: Asthma Treatment: Subjects remained on their usual prophylactic therapy of at least the maximum licensed dose of beclomethasone dipropionate (BDP) or equivalent during the 2-week baseline period, and their usual beta2-adrenoceptor agonist therapy was replaced by commercially available salbutamol 200µg Diskhaler (Ventodisks) to be used as required for symptomatic relief. Subjects were then randomised to receive either via the Diskhaler or matching placebo () BD in addition to their usual prophylactic therapy for 12 weeks. Objectives: To assess the efficacy and safety of inhaled via the Diskhaler when added to the existing therapy for moderate to severe asthmatic children. Primary Outcome/Efficacy Variable: Change from baseline in mean morning percent predicted peak expiratory flow (PEF). Secondary Outcome/Efficacy Variable(s): Mean evening percent PEF Diurnal variation Proportion of symptom-free days and symptom-free nights Day-time and night-time relief medication Global assessment of control of asthma Lung function measurements (PEF and forced expiratory volume at 1second (FEV1)) recorded at clinic visits Statistical Methods: The total sample (TOT; all subjects who received at least 1 puff of medication and recorded at least 1 day of valid diary or clinic data during the treatment period) was used for efficacy and safety analyses. Daily record booklet (DRB) data for analysis were grouped into the study periods: baseline (Weeks 1-2), treatment period 1 (Weeks 3-6), treatment period 2 (Weeks 7-10), treatment period 3 (Weeks 11-14), and follow-up (Weeks 15-16). All DRB variables and the subject assessment of asthma control were analysed using the van Elteren test adjusting for the values of the variables in the baseline period. For continuous data, the baseline data were categorised into 4 categories such that each category contained 1 quarter of the data. Confidence intervals (CIs) for the median treatment differences were not calculable. PEF and FEV1 were converted into percentage of predicted values and summarised statistically at each visit. The changes from baseline to Visit 5 were compared between treatment groups using analysis of covariance incorporating baseline values as a covariate. 95% CIs of the adjusted treatment mean differences were determined. Study Population: Male and female asthmatic children aged 4 to 16 years, inclusive, who had been taking at least 200mcg daily of BDP or equivalent for at least 6 months and who were symptomatic and demonstrated a mean PEF of 90% or less of predicted normal on at least 4 days of baseline. Subjects excluded were those receiving oral 2- adrenoceptor agonist therapy or maintenance oral corticosteroid therapy or those who had a short course of oral corticosteroids in the two weeks prior to the start of the baseline period. Also excluded were those who had received newly prescribed asthma therapy, or had changed asthma therapy in the two weeks prior to the start of the baseline period. Number of Subjects: Planned, N Randomised, N a Completed, n (%) 77 (77) 89 (81) Total Number Subjects Withdrawn*, N (%) 22 (22) 18 (16) Withdrawn due to Adverse Events, n (%) 4 (4) 2 (2) 1
2 Withdrawn due to Lack of Efficacy, n (%) 1 (1) 2 (2) Withdrawn for other reasons, n (%) 18 (18) 15 (14) a One subject in the SAL group and 3 subjects in the group and were considered to have unevaluable data and were excluded from all analyses. *subjects could withdraw due to more than one reason N (TOT) Females: Males 40:59 42:65 Mean Age, years (SD) 10.2 (2.7) 10.3 (2.7) Race, n (%) Not available (NA) NA Primary Efficacy Results: Total sample Change from baseline in mean morning percent predicted PEF Median Lower quartile, upper quartile 2.6, , 8.6 Interquartile range Minimum, maximum -34.8, , 28.0 p-value <0.001 Median Lower quartile, upper quartile 3.0, , 13.2 Interquartile range Minimum, maximum -5.3, , 30.4 p-value Median Lower quartile, upper quartile 2.6, , 11.2 Interquartile range Minimum, maximum -13.8, , 52.6 p-value Median Lower quartile, upper quartile -1.7, , 10.5 Interquartile range Minimum, maximum -21.0, , 54.4 p-value Secondary Outcome Variable(s): Total sample Change from baseline in mean evening percent predicted PEF NA Median Lower quartile, upper quartile -0.9, , 6.4 Interquartile range Minimum, maximum -29.3, , 24.3 Median Lower quartile, upper quartile 1.7, , 9.1 Interquartile range Minimum, maximum -10.7, ,
3 Median Lower quartile, upper quartile -1.8, , 8.1 Interquartile range Minimum, maximum -18.3, , 47.7 Median Lower quartile, upper quartile -4.5, , 9.1 Interquartile range Minimum, maximum -19.8, , 47.7 Change from baseline in diurnal variation (%) Median Lower quartile, upper quartile -5.9, , 0.5 Interquartile range Minimum, maximum -29.3, , 15.9 Median Lower quartile, upper quartile -8.1, , -0.1 Interquartile range Minimum, maximum -25.0, , 11.0 N subjects (N missing) [N present] 82 (15) [97] 95 (11) [106] Median Lower quartile, upper quartile -9.0, , -0.2 Interquartile range Minimum, maximum -23.5, , 17.2 N subjects (N missing) [N present] 78 (4 ) [82] 89 (6) [95] Median Lower quartile, upper quartile -8.0, , 0.6 Interquartile range Minimum, maximum -23.8, , 19.0 Change from baseline in proportion of symptom-free days Median Lower quartile, upper quartile 0.00, , 0.21 Interquartile range Minimum, maximum -0.85, , 0.89 Median Lower quartile, upper quartile 0.00, , 0.36 Interquartile range Minimum, maximum -1.00, , 0.89 Median
4 Lower quartile, upper quartile 0.00, , 0.41 Interquartile range Minimum, maximum -0.55, , 0.97 Median Lower quartile, upper quartile 0.00, , 0.57 Interquartile range Minimum, maximum -0.55, , 1.00 Change from baseline in proportion of symptom-free nights Median Lower quartile, upper quartile -0.04, , 0.25 Interquartile range Minimum, maximum -0.79, , 0.73 Median Lower quartile, upper quartile -0.01, , 0.33 Interquartile range Minimum, maximum -0.96, , 0.83 Median Lower quartile, upper quartile -0.01, , 0.35 Interquartile range Minimum, maximum -0.47, , 0.75 Median Lower quartile, upper quartile -0.10, , 0.33 Interquartile range Minimum, maximum -0.62, , 0.86 Change from baseline in use of day-time relief medication (blisters) Median Lower quartile, upper quartile -0.8, , 0.1 Interquartile range Minimum, maximum -5.0, , 4.0 N subjects (N missing) [N present] 97 (2) [99] 107 (0) [107] Median Lower quartile, upper quartile -1.4, , 0.0 Interquartile range Minimum, maximum -6.0, , 4.2 Median Lower quartile, upper quartile -1.4, , 0.3 Interquartile range Minimum, maximum -6.0, , 4.5 4
5 N subjects (N missing) [N present] 77 (5) ]82] 89 (6) [95] Change from baseline in use of night-time relief medication (blisters) Median Lower quartile, upper quartile -0.4, , 0.2 Interquartile range Minimum, maximum -1.7, , 1.9 N subjects (N missing) [N present] 98 (1) [99] 105 (2) [107] Median Lower quartile, upper quartile -0.4, , 0.2 Interquartile range Minimum, maximum -1.4, , 2.1 N subjects (N missing) [N present] 80 (17) [97] 94 (12) 106 Median Lower quartile, upper quartile -0.3, , 0.3 Interquartile range Minimum, maximum -1.9, , 2.9 N subjects (N missing) [N present] 75 (7) [82] 86 (9) [95] Subject s global assessment of control of asthma at Visit 5 Very good, n (%) 19 (26) 12 (13) Good, n (%) 18 (24) 27 (30) Not bad, n (%) 31 (42) 43 (48) Bad, n (%) 6 (8) 8 (9) Parent s global assessment of control of asthma at Visit 5 Very good, n (%) 20 (25) 18 (20) Good, n (%) 29 (37) 26 (29) Not bad, n (%) 25 (32) 35 (39) Bad, n (%) 5 (6) 10 (11) Physician s global assessment of control of asthma at Visit 5 Very effective, n (%) 18 (23) 15 (17) Effective, n (%) 23 (29) 23 (26) Satisfactory, n (%) 28 (35) 31 (34) Ineffective, n (%) 10 (13) 21 (23) Global assessment of control of asthma at Visit 5 (level of activity restriction) Never, n (%) 28 (35) 33 (37) Sometimes, n (%) 39 (49) 38 (43) Frequently, n (%) 10 (13) 16 (18) Always, n (%) 2 (3) 2 (2) Change from baseline to Visit 5 in percent predicted PEF recorded at the clinic visits Mean (SD) 6.8 (20.9) 1.2 (16.7) Minimum, maximum -59.1, , 40.6 Change from baseline to Visit 5 in percent predicted FEV1 recorded at the clinic visits 5
6 Mean (SD) 5.2 (20.0) 1.8 (15.7) Minimum, maximum -60.1, , 41.5 Safety Results: Most Frequent Adverse Events (AEs) On Therapy n (%) n (%) Subjects with any AE(s), n (%) 74 (75) 81 (76) Exacerbation of asthma 23 (23) 19 (18) Headache 20 (20) 9 (8) Sore throat 14 (14) 6 (6) Cough 12 (12) 14 (13) Wheezing 12 (12) 12 (11) Upper respiratory infection 11 (11) 11 (10) Acute nasopharyngitis 8 (8) 12 (11) Tonsillitis 5 (5) 2 (2) Fever 5 (5) 1 (1) Stomach ache 4 (4) 2 (2) Seasonal allergic rhinitis 4 (4) 4 (4) Chest infection 2 (2) 9 (8) Asthma attack 2 (2) 5 (5) Eczema 1 (1) 4 (4) Chest pain 2 (2) 4 (4) Serious Adverse Events (SAEs) - On Therapy n (%) [n considered by the investigator to be related to study medication] Subjects with non-fatal SAEs, n (%) 10 (10) [NA] 13 (12) [NA] SAEs n (%) [related] n (%) [related] Exacerbation of asthma 10 (10) [1] 8 (7) [3] Severe acute asthma 2 (2) [0] 0 Chest infection 1 (1) [0] 0 Virosis 1 (1) [0] 0 Eczema 0 2 (2) [0] Asthma attack 0 1 (<1) [0] Reduced PEF rate 0 1 (<1) [0] Shortness of breath 0 1 (<1) [0] Tonsillitis 0 1 (<1) [0] Fracture of carpal bone(s) 0 1 (<1) [0] Subjects with fatal SAEs, n (%) 0 0 Conclusion: See publication below Publications: Russell G, Williams DA, Weller P, Price JF. Salmeterol xinafoate in children on high dose inhaled steroids. Ann Allergy Asthma Immunol. 1995: 75(5); Date Updated: 08-Mar
Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: SAM40012 Title: A multicentre, randomised, double-blind, double-dummy, parallel group comparison of three treatments : 1)
Study No.: SAM40012 Title: A multicentre, randomised, double-blind, double-dummy, parallel group comparison of three treatments : 1) salmeterol/fluticasone propionate () (mcg strength) bd via DISKUS/ACCUHALER
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Co-Primary Outcomes/Efficacy Variables:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSecondary Outcome/Efficacy Variable(s):
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationG. Boyd on behalf of a UK Study group
Eur Respir J, 1995, 8, 1494 1498 DOI: 10.1183/09031936.95.08091494 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1995 European Respiratory Journal ISSN 0903-1936 Salmeterol xinafoate in
More informationSYNOPSIS THIS IS A PRINTED COPY OF AN ELECTRONIC DOCUMENT. PLEASE CHECK ITS VALIDITY BEFORE USE.
Drug product: Drug substance(s): Document No.: Edition No.: 1 Study code: Accolate Zafirlukast (ZD9188) 9188IL/0138 Date: 02 May 2007 SYNOPSIS A Multicenter, Randomized, Double-blind, -controlled, Parallel
More informationIndication: Treatment: Objectives: Primary Outcome/Efficacy Variable: Secondary Outcome/Efficacy Variable(s): Statistical Methods:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives : Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSYNOPSIS. Co-ordinating investigator Not applicable. Study centre(s) This study was conducted in Japan (57 centres).
Drug product: Symbicort Turbuhaler Drug substance(s): ST (Symbicort Turbuhaler ) Edition No.: 1.0 Study code: D5890C00010 Date: 15 March 2007 SYNOPSIS An 8-week, randomised, double blind, parallel-group,
More informationUMEC/VI vs. UMEC in subjects who responded to UMEC UMEC/VI vs. VI in subjects who responded to VI
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationDual-Controller Asthma Therapy: Rationale and Clinical Benefits
B/1 Dual-Controller Asthma Therapy: Rationale and Clinical Benefits MODULE B The 1997 National Heart, Lung, and Blood Institute (NHLBI) Expert Panel guidelines on asthma management recommend a 4-step approach
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationIvax Pharmaceuticals UK Sponsor Submission to the National Institute for Health and Clinical Excellence
Ivax Pharmaceuticals UK Sponsor Submission to the National Institute for Health and Clinical Excellence Clinical and cost-effectiveness of QVAR for the treatment of chronic asthma in adults and children
More informationStudy No.: SFCA3007 Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial Evaluating the Safety and Efficacy of the DISKUS
Study No.: A3007 Title: A Randomized, Double-Blind, -Controlled, Parallel-Group Trial Evaluating the Safety and Efficacy of the DISKUS Formulations of Salmeterol (SAL) 50mcg BID and Fluticasone Propionate
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationScottish Medicines Consortium
Scottish Medicines Consortium budesonide/formoterol 100/6, 200/6 turbohaler (Symbicort SMART ) No. (362/07) Astra Zeneca UK Limited 9 March 2007 (Issued May 2007) The Scottish Medicines Consortium (SMC)
More informationOmalizumab (Xolair ) ( Genentech, Inc., Novartis Pharmaceuticals Corp.) September Indication
( Genentech, Inc., Novartis Pharmaceuticals Corp.) September 2003 Indication The FDA recently approved Omalizumab on June 20, 2003 for adults and adolescents (12 years of age and above) with moderate to
More informationType of intervention Treatment. Economic study type Cost-effectiveness analysis.
Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 micro g twice daily and budesonide 800 micro g twice daily in the treatment of adults and adolescents with asthma Lundback
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationADULT ASTHMA GUIDE SUMMARY. This summary provides busy health professionals with key guidance for assessing and treating adult asthma.
ADULT ASTHMA GUIDE SUMMARY This summary provides busy health professionals with key guidance for assessing and treating adult asthma. Its source document Asthma and Respiratory Foundation NZ Adult Asthma
More informationGuideline topic: Pharmacological management of asthma Evidence table 4.11b: Add-on drugs for inhaled steroids: Long acting or oral B2 agonists
1 of 8 09/05/2018, 11:41 Guideline topic: Pharmacological management of asthma Evidence table 4.11b: Add-on drugs for steroids: Long acting or oral B2 agonists Author Year Study type Quality rating Population
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationDR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL
DR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL Definition Guidelines contact complicated definitions Central to this is Presence of symptoms Variable airflow obstruction Diagnosis
More informationAllwin Mercer Dr Andrew Zurek
Allwin Mercer Dr Andrew Zurek 1 in 11 people are currently receiving treatment for asthma (5.4 million people in the UK) Every 10 seconds, someone is having a potentially life-threatening asthma attack
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationDiagnosis and Management of Asthma in Children based on the British Thoracic Society and Scottish Intercollegiate Guidelines Network September 2016
Diagnosis and Management of Asthma in Children based on the British Thoracic Society and Scottish Intercollegiate Guidelines Network September 2016 Diagnosis: There is no lower limit to the age at which
More informationTips on managing asthma in children
Tips on managing asthma in children Dr Ranjan Suri Consultant in Respiratory Paediatrics Bupa Cromwell Hospital Clinics: Friday (pm) Asthma in Children Making the diagnosis Patterns of childhood asthma
More informationAbstract Background Theophylline is widely used in the treatment of asthma, and there is evidence that theophylline has antiinflammatory
Thorax 2000;55:837 841 837 National Heart and Lung Institute, Imperial College School of Medicine and Royal Brompton Hospital, London SW3 6LY, UK S Lim A Jatakanon K F Chung P J Barnes Napp Laboratories
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Papi A, Canonica GW, Maestrelli P, et al. Rescue use of beclomethasone
More informationStudy No.:MPX Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationScottish Medicines Consortium
Scottish Medicines Consortium montelukast 10mg tablets (Singulair ) No. (185/05) Merck, Sharp & Dohme Ltd (MSD) New indication: for asthmatic patients in whom montelukast is indicated in asthma, montelukast
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationthe use of inhaled corticosteroids for at least 3 months preceding the study;
The cost effectiveness of chlorofluorocarbon-free beclomethasone dipropionate in the treatment of chronic asthma: a cost model based on a 1-year pragmatic, randomised clinical study Price D, Haughney J,
More informationmg 25 mg mg 25 mg mg 100 mg 1
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAsthma Assessment & Review
ASTHMA RESOURCE PACK Section 5B Asthma Assessment & Review In this section: 1. Primary Care initial assessment and review Asthma Resource Pack Section 5B: Asthma Assessment & Review Version 3.0 Last Updated:
More informationInclude patients: with a confirmed diagnosis of asthma who have been free of asthma symptoms for 3 months or more.
Corby Clinical Commissioning Group Kettering General Hospital NHS Trust Nene Clinical Commissioning Group rthampton General Hospital NHS Trust rthamptonshire Healthcare Foundation Trust Stepping down asthma
More informationGreater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma
Greater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma Non-pharmacological options for ALL patients, consider at ALL stages Make sure diagnosis
More informationASTRAZENECA v GLAXOSMITHKLINE
CASE AUTH/1833/5/06 ASTRAZENECA v GLAXOSMITHKLINE CONCEPT study leavepiece AstraZeneca complained that a leavepiece issued by Allen & Hanburys, part of GlaxoSmithKline, did not present a fair and balanced
More informationSUMMARY THIS IS A PRINTED COPY OF AN ELECTRONIC DOCUMENT. PLEASE CHECK ITS VALIDITY BEFORE USE.
i SUMMARY ZENECA PHARMACEUTICALS FINISHED PRODUCT: ACTIVE INGREDIENT: ACCOLATE zafirlukast (ZD9188) Trial title (number): A Dose-ranging, Safety and Efficacy Trial with Zafirlukast (ACCOLATE ) in the Treatment
More informationDual-controller therapy, or combinations REVIEW DUAL-CONTROLLER REGIMENS I: DATA FROM RANDOMIZED, CONTROLLED CLINICAL TRIALS.
DUAL-CONTROLLER REGIMENS I: DATA FROM RANDOMIZED, CONTROLLED CLINICAL TRIALS Samy Suissa, PhD ABSTRACT Dual-controller therapy, or combinations of 2 or more pharmacotherapies with complementary mechanisms
More informationSYNOPSIS A two-stage randomized, open-label, parallel group, phase III, multicenter, 7-month study to assess the efficacy and safety of SYMBICORT
Drug product: Drug substance(s): Edition No.: Study code: SYMBICORT pmdi 160/4.5 g Budesonide/formoterol D5896C00005 Date: 8 May 2006 SYNOPSIS A two-stage randomized, open-label, parallel group, phase
More informationroflumilast 500 microgram tablets (Daxas ) SMC No. (635/10) Nycomed Ltd
roflumilast 500 microgram tablets (Daxas ) SMC No. (635/10) Nycomed Ltd 06 August 2010 (Issued 10 September 2010) The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationaclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.
aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationfluticasone furoate / vilanterol 92/22, 184/22 micrograms inhalation powder (Relvar Ellipta ) SMC No. (966/14) GlaxoSmithKline UK
fluticasone furoate / vilanterol 92/22, 184/22 micrograms inhalation powder (Relvar Ellipta ) SMC No. (966/14) GlaxoSmithKline UK 09 May 2014 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPathology of Asthma Epidemiology
Asthma A Presentation on Asthma Management and Prevention What Is Asthma? A chronic disease of the airways that may cause Wheezing Breathlessness Chest tightness Nighttime or early morning coughing Pathology
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable(s):
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationT he use of inhaled corticosteroids to control the inflammatory
791 ORIGINAL ARTICLE Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose D Price, D Dutchman, A Mawson, B Bodalia, S Duggan, P Todd on behalf of the
More informationmeasured Improvement in am PEFR FP vs BUD gave +11l/min FP vs BDP gave nonsignificant improvement in PEFR +3l/min FP: BUD ratio 1.
1 of 8 09/05/2018, 11:29 Guideline topic: Pharmacological management of asthma Evidence table 4.25: Budesonide vs Beclomethasone Different inhaled corticosteroids (ICS) flixotide propionate (FP) vs budesonide
More informationStudy No: Title: Rationale: . Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationJames P. Kemp, MD; Margaret C. Minkwitz, PhD; Catherine M. Bonuccelli, MD; and Marshelle S. Warren, MD
Therapeutic Effect of Zafirlukast as Monotherapy in Steroid-Naive Patients With Severe Persistent Asthma* James P. Kemp, MD; Margaret C. Minkwitz, PhD; Catherine M. Bonuccelli, MD; and Marshelle S. Warren,
More informationSYNOPSIS. Study center(s) This study was conducted in the United States (128 centers).
Drug product: Drug substance(s): Document No.: Edition No.: Study code: Date: SYMBICORT pmdi 160/4.5 µg Budesonide/formoterol SD-039-0725 17 February 2005 SYNOPSIS A Twelve-Week, Randomized, Double-blind,
More informationNot available 100/6mcg 2 BD formoterol (Fostair MDI) 100/6mcg 33
COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP FLUTICASONE FUROATE/VILANTEROL COMBINATION INHALER - ASTHMA Policy agreed by Vale of York CCG (date) Drug, Treatment, Device name Fluticasone
More informationManagement of wheeze in pre-school children. Prof Colin Robertson, Respiratory Medicine, Royal Children s Hospital, Melbourne
Management of wheeze in pre-school children Prof Colin Robertson, Respiratory Medicine, Royal Children s Hospital, Melbourne General Practitioner encounters for asthma Asthma in Australia, 2003 Emergency
More informationChildhood Asthma. The pathophysiology of asthma is an interplay. CME Case Study. Case Study. By Moyez B. Ladhani, MD, CCFP, FAAP, FRCPC
CME Case Study Childhood Asthma By Moyez B. Ladhani, MD, CCFP, FAAP, FRCPC Case Study A two-year-old child presents to your office with a cough, which has been present for three weeks. It is worse at nighttime
More informationTreatment of acute asthmatic exacerbations with an increased dose of inhaled steroid
12 Paediatrics and Child Health, Dunedin School of Medicine, PO Box 913, University of Otago Medical School, Dunedin, New Zealand J Garrett Preventive and Social Medicine, Dunedin School of Medicine S
More informationInternational Co-ordinating investigator None appointed.
Drug product: Budesonide/formoterol SYNOPSIS Drug substance(s): Budesonide/formoterol Document No.: SD-039-CR-0673 Referring to part Edition No.: 1 of the dossier Study code: SD-039-0673 Date: 13 June,
More informationDiagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma
Diagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma Magnitude of Asthma - India Delhi Childhood asthma: 10.9% Adults: 8% Other Cities 3 to 18% Chhabra SK et al Ann Allergy Asthma
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More information(Asthma) Diagnosis, monitoring and chronic asthma management
Dubai Standards of Care 2018 (Asthma) Diagnosis, monitoring and chronic asthma management Preface Asthma is one of the most common problem dealt with in daily practice. In Dubai, the management of chronic
More informationBreakfast Session Prof Neil Barnes Professor of Respiratory Medicine London Chest Hospital & The Royal London Hospital United Kingdom
Breakfast Session Prof Neil Barnes Professor of Respiratory Medicine London Chest Hospital & The Royal London Hospital United Kingdom 2 BEYOND SYMPTOMS ADDRESSING FUTURE RISK IN ASTHMA South GP CME 2013,
More informationSponsor. Generic drug name. Trial indication(s) Protocol number. Protocol title. Clinical trial phase. Study Start/End Dates.
Sponsor Novartis Generic drug name Fluticasone propionate Trial indication(s) Moderate-severe bronchial asthma Protocol number CQAE397A2202 Protocol title A randomized open label study to assess the utility
More informationHM2008/00566/00. study and to obtain clinical experience with the use of this drug. Primary Outcome/Efficacy Variable(s): <Pharmacokinetics>
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSYNOPSIS. Study centres This was a multicentre study conducted in 53 centres in Sweden.
Drug product: Symbicort Turbuhaler Drug substance(s): Budesonide/Formoterol Edition No.: 1 Study code: LD-039-0003 Date: 20 May 2005 SYNOPSIS An open, randomized, parallel group, multicentre, phase IIIB
More informationTreatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark
Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting
More informationInhaled Corticosteroids for the Treatment of Chronic Asthma in Adults & Adolescents aged 12 years & over
Manufacturer Submission To The National Institute for Health and Clinical Excellence By GlaxoSmithKline UK Inhaled Corticosteroids for the Treatment of Chronic Asthma in Adults & Adolescents aged 12 years
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAlberta Childhood Asthma Pathway for Primary Care
Asthma Diagnosis Box 1 Diagnosis: Based on symptom pattern, careful and thorough history of symptoms (wheeze, cough, night waking and activity limitations), and assessment of family history of asthma and
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES Document Description Document Type Service Application Version Guidelines All healthcare professionals(hcps) caring for patients with asthma
More informationStudy No Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable(s):
Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe clinical effectiveness and costeffectiveness. treatment of chronic asthma in children under the age of 12 years
The clinical effectiveness and costeffectiveness of corticosteroids for the treatment of chronic asthma in children under the age of 12 years Submission of evidence from AstraZeneca UK Ltd regarding the
More informationGet Healthy Stay Healthy
Asthma Management WHAT IS ASTHMA? Asthma causes swelling and inflammation in the breathing passages that lead to your lungs. When asthma flares up, the airways tighten and become narrower. This keeps the
More informationRelvar Ellipta (fluticasone furoate/vilanterol [as trifenatate]) for the treatment of patients with asthma
Relvar Ellipta (fluticasone furoate/vilanterol [as trifenatate]) for the treatment of patients with asthma Evidence Summary to support formulary decision making and guideline development Prescribing and
More informationSYNOPSIS. Date 15 June 2004
Drug product Drug substance(s) Document No. Edition No. Study code SYMBICORT pmdi 160/4.5 mg per actuation Budesonide/formoterol SD-039-0719 Date 15 June 2004 SYNOPSIS A Six-Month, Randomized, Open-Label
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE December 2014 Review Date: December 2017 Bulletin 206 : DuoResp Spiromax 160 / 4.5 and 320 / 9 budesonide & formoterol dry powder inhaler JPC Recommendations
More informationSponsor Novartis Consumer Health, SA. Generic Drug Name
Sponsor Novartis Consumer Health, SA Generic Drug Name Xylometazoline Hydrochloride Trial Indication(s) For the symptomatic relief of nasal congestion due to colds, hayfever or other allergic rhinitis,
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationKewKM,KarnerC,MindusSM,FerraraG. Cochrane Database of Systematic Reviews.
Cochrane Database of Systematic Reviews Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children(review)
More informationCates CJ, Lasserson TJ
Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in Cates CJ, Lasserson TJ This is a reprint of a Cochrane review, prepared
More informationSYNOPSIS. Drug substance(s) Budesonide/formoterol Document No. Edition No. Study code SD Date 16 December 2004
Drug product SYMBICORT pmdi 160/4.5 µg SYNOPSIS Drug substance(s) Budesonide/formoterol Document No. Edition No. Date 16 December 2004 A Twelve-Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled
More informationAsthma training. Mike Levin Division of Asthma and Allergy Red Cross Hospital
Asthma training Mike Levin Division of Asthma and Allergy Red Cross Hospital Introduction Physiology Diagnosis Severity Treatment Control Stage 3 of guidelines Acute asthma Drug delivery Conclusion Overview
More informationSummary of the risk management plan (RMP) for Nucala (mepolizumab)
EMA/671186/2015 Summary of the risk management plan (RMP) for Nucala (mepolizumab) This is a summary of the risk management plan (RMP) for Nucala, which details the measures to be taken in order to ensure
More informationSYNOPSIS. First subject enrolled 15 August 2003 Therapeutic confirmatory (III) Last subject completed 03 February 2005
Drug product: SYMBICORT pmdi 160/4.5 μg Drug substance(s): Budesonide/formoterol Study code: SD-039-0728 Edition No.: FINAL Date: 27 February 2006 SYNOPSIS A 52-week, randomized, double-blind, single-dummy,
More informationFormoterol versus short-acting beta-agonists as relief medication for adults and children with asthma (Review)
Formoterol versus short-acting beta-agonists as relief medication for adults and children with asthma (Review) Welsh EJ, Cates CJ This is a reprint of a Cochrane review, prepared and maintained by The
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPotency ratio fluticasone propionate (Flixotide Diskus)/budesonide (Pulmicort Turbuhaler)
Respiratory Medicine (2007) 101, 610 615 Potency ratio fluticasone propionate (Flixotide Diskus)/budesonide (Pulmicort Turbuhaler) Björn Ställberg a, Eva Pilman b, Bengt-Eric Skoogh c,, Bengt Arne Hermansson
More informationASTHMA & RESPIRATORY FOUNDATION NZ ADULT ASTHMA GUIDELINES: A QUICK REFERENCE GUIDE 1
ASTHMA & RESPIRATORY FOUNDATION NZ ADULT ASTHMA GUIDELINES: A QUICK REFERENCE GUIDE 1 1. Richard Beasley, Bob Hancox, Matire Harwood, Kyle Perrin, Betty Poot, Janine Pilcher, Jim Reid, Api Talemaitoga,
More informationBudesonide treatment of moderate and severe asthma in children: A doseresponse
Budesonide treatment of moderate and severe asthma in children: A doseresponse study Soren Pedersen, MD, PhD, and Ove Ramsgaard Hansen, MD Kolding, Denmark Objective: The purpose of the study was to evaluate
More informationMedicine Dr. Kawa Lecture 4 - Treatment of asthma :
Medicine Dr. Kawa Lecture 4 - Treatment of asthma : Avoiding allergens. Hyposensitization :Subcutaneous injections of inially very small, but gradually increasing doses of allergens (desensitization or
More informationNG80. Asthma: diagnosis, monitoring and chronic asthma management (NG80)
Asthma: diagnosis, monitoring and chronic asthma management (NG80) NG80 NICE has checked the use of its content in this product and the sponsor has had no influence on the content of this booklet. NICE
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 15 December 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 December 2010 HIROBRIZ BREEZHALER 150 micrograms, inhalation powder, hard capsules B/10 with inhaler (CIP code:
More informationInternational Journal of Medical Research & Health Sciences
International Journal of Medical Research & Health Sciences www.ijmrhs.com Volume 2 Issue 3 July - Sep Coden: IJMRHS Copyright @2013 ISSN: 2319-5886 Received: 23 th May 2013 Revised: 24 th Jun 2013 Accepted:
More informationStudy No.: ADF Title: Phase III study of adefovir dipivoxil (ADV) tablets in patients with compensated chronic hepatitis B -comparative study
Study No.: ADF105220 Title: Phase III study of adefovir dipivoxil () tablets in patients with compensated chronic hepatitis B -comparative study against lamivudine ()- Rationale: This study wass a confirmatory
More information